
|Articles|December 3, 2007
Fovea and Genzyme enter gene therapy collaboration
Fovea Pharmaceuticals has entered into a collaborative research agreement with Genzyme Corporation.
Advertisement
Fovea Pharmaceuticals has entered into a collaborative research agreement with Genzyme Corporation.
The alliance is based around Fovea's proprietary high content technology platform that allows the identification of new targets involved in photoreceptor degeneration in retinal dystrophies.
The two companies will collaborate to develop gene related therapies using this technology together with Genzyme's gene delivery techniques.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Why ST-100 is expanding from dry eye into corneal wound healing
2
Eichenbaum Acorns: Building the private academic model with Jeffrey S. Heier, MD
3
ONL Therapeutics completes enrollment in Phase 2 GALAXY trial for geographic atrophy
4
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
5
















